Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Medicina (Kaunas). 2024 Aug 6;60(8):1272. doi: 10.3390/medicina60081272.
The overall- and progression-free survival rates of Hodgkin's lymphoma patients have improved. Our goal was to examine the changes in our treatment results and their causes depending on the daily diagnostic and therapeutic practice. We analysed data of 776 classical Hodgkin lymphoma patients treated between 1980 and 2019. Patient data were investigated in ten-year periods (first period: 1980-1989, second period: 1990-1999, third period: 2000-2009, and fourth period: 2010-2019). Radiotherapy alone as a first-line treatment was used progressively less often, and in the 4th period it was no longer used before or without chemotherapy. The use of combined chemo- and radiotherapy decreased in the last period, and the number of those patients who received only chemotherapy increased significantly. The 10-year overall survival improved significantly from 1990 to 1999 compared to 2010 to 2019 (74.9% vs. 86.9%). About 30% of patients relapsed after or were refractory to first-line therapy in each period. The incidence of relapse in the last period did not increase after two years, but there was no significant difference between the periods. Overall survival rates of HL patients have improved significantly in recent decades, which is due to improved diagnostic methods and modern therapies. Progression-free survival is unchanged; one-third of patients relapse or are refractory to first-line treatment within the first two years. Early recognition of R/R patients, the early application of newer and already available innovative therapies, and the finding of additional new and effective therapies are of particular importance.
霍奇金淋巴瘤患者的总生存率和无进展生存率均有所提高。我们的目标是检查根据日常诊断和治疗实践，我们的治疗结果及其原因的变化。我们分析了 1980 年至 2019 年间治疗的 776 例经典霍奇金淋巴瘤患者的数据。以十年为一个时间段（第一个时间段：1980-1989 年；第二个时间段：1990-1999 年；第三个时间段：2000-2009 年；第四个时间段：2010-2019 年）对患者数据进行了研究。单独放疗作为一线治疗的方法使用得越来越少，在第四个时间段，它在化疗之前或没有化疗的情况下不再使用。联合化疗和放疗的使用在最后一个时间段减少，仅接受化疗的患者数量显著增加。1990 年至 1999 年与 2010 年至 2019 年相比，10 年总生存率显著提高（74.9%比 86.9%）。每个时间段约有 30%的患者在一线治疗后复发或耐药。在最后一个时间段，两年后复发的发生率没有增加，但各时间段之间没有显著差异。近年来，HL 患者的总生存率显著提高，这归因于诊断方法的改进和现代治疗方法的应用。无进展生存率保持不变；三分之一的患者在头两年内复发或对一线治疗耐药。早期识别 R/R 患者，早期应用新的和现有的创新疗法，以及发现其他新的有效疗法尤为重要。
